Role of oral contraceptives in the growth of a multilobular adenoma associated with a hepatocellular carcinoma in a young woman

Journal of Hepatology

Volumn 25, Issue 6, 1996, Pages 976-979

  Perret, Anne Gentil ^a   Mosnier, Jean François ^b   Porcheron, Jack ^b   Cuilleron, Muriel ^b   Berthoux, Patricia ^b   Boucheron, Simonne ^b   Audigier, Jean Christian ^b  

^a SERVICE DE NEUROLOGIE   (France)

^b NONE

Author keywords

Estrogen; Hepatocellular carcinoma; Multilobular hepatocellular adenoma; Oral contraceptives; Progesterone

Indexed keywords

ESTROGEN RECEPTOR; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CARCINOGENESIS; CASE REPORT; CELL GROWTH; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER ADENOMA; LIVER CELL; LIVER CELL CARCINOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030457979     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80305-9     Document Type: Article

References (25)

1. 1. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol 1988; 19: 784-94.
2. 2. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983; 48: 437-40.
3. 3. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986; 292: 1355-7.
4. 4. Forman D, Vincent TJ, Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J 1986; 292: 1357-61.
5. 5. Palmer JR, Rosenberg L, Kaufmann DW, Warshauer NE, Stolley P, Shapiro S. Oral contraceptive use and liver cancer. Am J Epidemiol 1989; 130: 878-82.
6. 6. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993, 67: 635-7.
7. 7. Mant JWF, Vessey MP. Trends in mortality from primary liver cancer in England and Wales 1975-92: influence of oral contraceptives. Br J Cancer 1995, 72: 800-3.
8. 8. Anthony PP. Drug-induced liver tumors. Gastroenterol Clin Biol 1993; 17: 54-8.
9. 9. Okamoto H, Okada S, Sugiyama Y. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′ non-coding region. Jpn J Exp Med 1990, 60: 215-22.
10. 10. Saez S, Martin P, Chouvet C. Estradiol and progesterone receptor levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Research 1978, 38: 3468-73.
11. 11. Flejou J-F, Barge J, Menu Y, Degott C, Bismuth H, Potet F, Benhamou JP. Liver adenomatosis: an entity distinct from liver adenoma? Gastroenterology 1985; 89: 1132-8.
12. 12. Tesluk H, Lawrie J. Hepatocellular adenoma: its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981; 105: 296-99.
13. 13. Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, Schiff ER. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986; 105: 547-49.
14. 14. Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 1989; 110: 489-90
15. 15. Tao LC. Are oral contraceptive-associated liver cell adenomas premalignant? Acta Cytol 1992; 36: 338-44.
16. 16. Ferrell L, Crawford J, Dhillon A, Scheuer P, Nakanuma Y. Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol 1993, 17: 1113-23.
17. 17. Baum JK, Holtz F, Bookstein JJ, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2: 926-9.
18. 18. Edmondson HA, Henderson B, Benton B. Liver cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294: 470-2.
19. 19. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86: 180-2.
20. 20. Neuman I, Thierau D, Andrae U, Greim H, Schwartz LR. Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in γ-glutamyl-transpeptidase-positive cells. Carcinogenesis 1992; 13: 373-8.
21. 21. Rabe T, Feldmann K, Grunwald K, Runnebaum B. Liver tumours in women on oral contraceptives. Lancet 1994; 344: 1568-9.
22. 22. O'Malley B. The steroid receptor superfamily: more excitement predicted for the future. Mol Endocrinol 1990, 4: 363-9.
23. 23. Ferrell L. Hepatocellular carcinoma arising in a focus of multilobular adenoma. A case report. Am J Surg Pathol 1993; 17: 525-9.
24. 24. Tomimatsu M, Ishiguro N, Taniai M, Okuda H, Saito A, Obata H, Yamamoto M, Takasaki K, Nakano M. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993; 72: 683-8.
25. 25. De Miti MS, Poussin K, Baccarini P, D'Errico A, Grigioni W, Pisi E, Bréchot C, Paterlini P. Selective persistence of HCV genotype 1b in liver cancer developing without cirrhosis. Hepatology 1994; 20: 200A (abstract).